Popular Articles
Natural Remedies

British Men Think Talking About Impotence Is "Just Not Cricket"
With the first innings of the Ashes commencing this week, celebrity TV
generic viagra online
NOW Election Highlights Debate Over Strategy For Future Of Feminist Movement
The AP/Kansas City Star on Sunday examined how the upcoming election for the next president of the National Organization for Women has brought to the forefront a debate over how the feminist movement should define itself moving forward. NOW President Kim Gandy is stepping down after eight years in which she led the group in opposition to many of former President George W. Bush"s policies. Running to replace her are Latifa Lyles, a 33-year-old who serves as a vice president to Gandy, and Terry O"Neill, a 56-year-old who served as NOW"s vice president for membership from 2001 to 2005. Lyles, who is black, would be NOW"s youngest president while O"Neill, who is white, would be its oldest to start a term. According to the AP/Star, the election represents "both an unusual clash of generations and an opportunity for activists to confront some of the challenges facing the feminist movement." The election will be held at NOW"s conference in Indianapolis this weekend.The candidates share the goals of ensuring that women"s needs are represented in health care reform and economic recovery efforts, and they both support working to make abortion and birth control more accessible. Lyles said she contrasts with NOW"s current membership, which is mostly white and older than age 40. Lyles believes she could help give the organization a more diverse, younger image and help encourage participation from a broader range of women. "The profile of NOW is just as important as the work we do," she said, adding, "There are a lot of antiquated notions about what feminism is." Gandy, who has endorsed Lyles, said, "It"s hard to ignore the fact there"s been a generational shift in the country, and an organization that doesn"t recognize that is living in the past." She added that Lyles" "youth is not a detriment, but an advantage. ... She"ll take NOW to a different level." Jessica Valenti, a prominent younger feminist and founder of the blog Feministing, said, "This could be the moment where NOW becomes super-relevant to the feminist movement again."O"Neill said she would focus on grassroots organizing and membership recruitment. She said that "even with a friend in the White House and a lot of friends in the Congress, it"s going to take well-organized, grassroots movement to advance our agenda." O"Neill added, "I keep hearing "Terry, I want to see more activism in my community,"" adding, "The press releases, the media exposure, invitations to the White House -- these are excellent things, but they"re not enough. The grass roots are not personally engaged." Former NOW President Patricia Ireland, who supports O"Neill, said, "There is a role that requires us to take unpopular stands and push on our friends. That"s what I think [O"Neill] really gets. She"s the one I believe will be very willing to use a wide array of tactics -- not just traditional letters and e-mails, but also engage in civil disobedience, organize fasts, be at some congressman"s district office" (Crary, AP/Kansas City Star, 6/14).
News of the day
NOVAVAX Achieves Pandemic H1N1 Influenza Production Milestone
Novavax, Inc. (Nasdaq: NVAX) announced it has manufactured a virus-like particle (VLP) vaccine candidate against the H1N1 pandemic influenza virus under current good-manufacturing practices (cGMP) at its new vaccine manufacturing facility in Rockville, MD. This milestone was accomplished in only 11 weeks after receiving the gene sequence for the H1N1 strain from the U.S. Centers for Disease Control. The Company was able to reach this manufacturing goal by employing proprietary, novel production technology which is not dependent on growing influenza virus in eggs. Chicken eggs are used to produce almost all of the world"s influenza vaccine supply. In addition, Novavax has produced essential reagents for measuring vaccine potency. The Company also has plans to produce additional batches of the pandemic H1N1 VLP vaccine to support human clinical studies and stands ready to assist with additional public health needs in the US as well as foreign countries.
Nutrition

There Is Enormous Waste In The Production And Reporting Of Research Evidence

In a viewpoint published Online First and in a future edition of The Lancet, Sir Iain Chalmers, of the James Lind Library, Oxford, UK, and Professor Paul Glasziou, of the University of Oxford, UK, debate on the unnecessary waste that exists in medical research. This misuse leads many reports to be of no purpose. If there is a lack of functional reports and if they are not easily accessible, research is of no help to patients or their doctors. The authors examine the causes and levels of waste in the four following stages: ò€¢ The choice of research questions ò€¢ The quality of research design and methods ò€¢ The adequacy of publication practices ò€¢ The quality of research reports They debate on how public funding of research is moderately linked with disease burden, for the choice of research questions. When analyzing 344 studies, it appears that only nine compared researchers" priorities with those of patients or doctors. Also, these nine studies showed striking mismatches. For example: Patients with osteoarthritis of the knee and the clinicians looking after them considered as a priority additional evaluation of physiotherapy and surgery, and assessment of educational and coping strategies. Only 9 percent of patients wanted more research on drugs, yet over 80 percent of randomised controlled trials in patients with osteoarthritis of the knee were drug evaluations. This example is not limited to commercial research. Controlled trials funded by the UK Medical Research Council and British medical research charities were more probably drug trials than were trials commissioned by what is now the National Institute for Health Research (NIHR). For quality of research design, the authors explain: "New research should not be done unless, at the time it is initiated, the questions it proposes to address cannot be answered satisfactorily with existing evidence." New research is frequently inadequate as it is unable to deal with other fundamental issues. For example, in a sample of 234 clinical trials in the major medical journals, concealment of treatment allocation sequence was either inadequate (18 percent) or unclear (26 percent). There has been a great deal of argument lately on the inadequacy of publishing practices, specifically biased under-publication and over-publication of research. The authors mention that the public has become conscious of this matter thanks to exposure of suppressed evidence about serious adverse effects of treatments. In addition, studies showing disappointing results are less likely to be reported promptly, and are less likely to progress from abstracts to full reports. The authors write: "The problem of biased under-reporting of research results mainly from decisions taken by research sponsors and researchers, not from journal editors rejecting submitted reports." They continue by saying that public access to full results of all research is still only a hope. It remains that way because of the resistance of some research sponsors and researchers. At last, biased or unusable reports of research can be frequent. Some reports do not take into account adverse events. Sometimes there is a change in their primary outcomes between the protocol for the research and the published report. But even with impartiality, a report must still be appropriate for use by the end-user. There are two possible ways to improve studies according to the authors: 1- If clinicians are going to use the evidence showing beneficial effect of an intervention, the intervention needs to be adequately described (particularly when it is not a drug, like for example setting up a stroke unit or details of a low fat diet). 2- Evidence must be set in the context of updated systematic reviews. However, among the world"s major medical journals, The Lancet is the only one in requiring reports of new research to be preceded by and to conclude with reference to systematic reviews of other relevant evidence. The authors comment: "Since research must pass through all four stages...the waste is cumulative. If the losses estimated in the figure apply more generally, then the roughly 50% loss at stages 2, 3, and 4 would lead to a greater than 85% loss, which implies that the dividends from tens of billions of dollars of investment in research are lost every year because of correctable problems." In conclusion, the authors give several recommendations for each of the four areas, including: ò€¢ Growing involvement of clinicians and patients in determining the research. ò€¢ All journals should require new studies to be situated in the context of existing published research. ò€¢ Once research is completed, there should be support of timely open access to the complete results. ò€¢ There should be a supplement of peer review of studies with review by methodologists and end users. ò€¢ There should be support for free access repositories (separate from any publications, in order for clinicians and researchers to have the details of the treatments, test or instruments studied). "Avoidable waste in the production and reporting of research evidence" Iain Chalmers, Paul Glasziou DOI: 10.1016/S0140-6736(09)60329-9 thelancet Written by Stephanie Brunner (B.A.) Copyright: Medical News Today Not to be reproduced without permission of Medical News Today


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):